van SonderenAPetit-PedrolMDalmauJTitulaerMJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290-301. doi:10.1038/nrneurol.2017.43
Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012;52(5):245-266. doi:10.2176/nmc.52.245
4.
van SonderenAAriñoHPetit-PedrolM, et al.The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521-528. doi:10.1212/WNL.0000000000002917
5.
MikamiTSuzukiHKomatsuKMikuniN. Influence of inflammatory disease on the pathophysiology of moyamoya disease and quasi-moyamoya disease. Neurol Med Chir (Tokyo). 2019;59(10):361-370. doi:10.2176/nmc.ra.2019-0059
6.
TakahashiYMikamiTSuzukiH, et al.Development of moyamoya disease after non-herpetic acute limbic encephalitis: A case report. J Clin Neurosci. 2018;53:250-253. doi:10.1016/j.jocn.2018.04.042
7.
BanwellBBennettJLMarignierR, et al.Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8
8.
KruppLBTardieuMAmatoMP, et al.International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-1267. doi:10.1177/1352458513484547
9.
WangAAGommermanJLRojasOL. Plasma cells: From cytokine production to regulation in experimental autoimmune encephalomyelitis. J Mol Biol. 2021;433(1):166655. doi:10.1016/j.jmb.2020.09.014
